Patricia Hurter biography
Dr. Patricia N. Hurter Ph.D. serves as Independent Director of the Company. Dr. Hurter has served as the Chief Executive Officer of Lyndra Therapeutics Inc., since September 2019. Prior to this, Dr Hurter most recently served as a Senior Vice President at Vertex since 2011, during which time her responsibilities grew to include all CMC and preclinical development activities of Vertex’s R&D portfolio, as well as the internal GMP manufacturing facility that provides drug substance and product for clinical development and commercial supply. From 2013 to 2014, she served as Interim Head of Global Regulatory Affairs at Vertex and oversaw the submission of the new drug application for Orkambi®, as well as several label expansions for Kalydeco®. She played a leadership role in the development and commercialization of five transformative therapies for Vertex: Incivek®, Kalydeco®, Orkambi®, Symdeko® and Trikafta®. Prior to joining Vertex in 2004, Dr. Hurter was Director, Formulation Design and Characterization for Merck where she was a key member of the early development team for Januvia®, a treatment for Type II diabetes. Dr. Hurter serves as a member of the Board of Trustees of Harvard Conservation Trust. She holds a Ph.D. in chemical engineering from the Massachusetts Institute of Technology, an M.S. in mechanical engineering from West Virginia University and earned a B.Sc. in chemical engineering, cum laude, from the University of KwaZulu-Natal in Durban, South Africa. The Board has concluded that Dr. Hurter possesses specific attributes that qualify her to serve as a member of our Board, including her experience in drug research and development, global regulatory affairs and GMP manufacturing.
What is the salary of Patricia Hurter?
As the Independent Director of Synlogic Inc, the total compensation of Patricia Hurter at Synlogic Inc is $193,365. There are 4 executives at Synlogic Inc getting paid more, with Aoife Brennan having the highest compensation of $1,793,870.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Patricia Hurter?
Patricia Hurter is 56, he's been the Independent Director of Synlogic Inc since 2019. There are 5 older and 11 younger executives at Synlogic Inc. The oldest executive at Synlogic Inc is Richard Shea, 68, who is the Independent Director.
What's Patricia Hurter's mailing address?
Patricia's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Insiders trading at Synlogic Inc
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
What does Synlogic Inc do?
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
What does Synlogic Inc's logo look like?
Synlogic Inc executives and stock owners
Synlogic Inc executives and other stock owners filed with the SEC include:
-
Aoife Brennan,
President, Chief Executive Officer, Director -
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc,
Pres, CEO & Director -
Antoine Awad,
Chief Operating Officer -
Richard Riese,
Chief Medical Officer -
Patricia Hurter,
Independent Director -
Peter Barrett,
Independent Chairman of the Board -
Richard Shea,
Independent Director -
Edward Mathers,
Independent Director -
Nick Leschly,
Independent Director -
Chau Khuong,
Independent Director -
Michael Burgess,
Independent Director -
Michael Slater,
Head of Regulatory Affairs -
David Hava,
Chief Scientific Officer -
Gregg Beloff,
Interim Chief Financial Officer -
Ajay Munshi,
VP of Corp. Devel. -
Adam Thomas,
Chief People Officer & Sec. -
Michael Jensen,
Chief Financial Officer -
Dr. Timothy K. Lu M.D., Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Michael Conlon,
VP of Corp. Devel. -
Brendan St. Amant,
Head of Legal -
Daniel Rosan,
Sr. VP & Head of Investor Relations -
Dr. Elizabeth Wolffe,
Head of Investor Relations & Corp. Communications -
Dr. David L. Hava Ph.D.,
Chief Scientific Officer -
Gregg D. Beloff J.D., M.B.A.,
Interim Chief Financial Officer -
Dr. James J. Collins Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Timothy K. Lu,
Co-Founder -
Todd Shegog,
See Remarks -
Scott D Sandell,
10% owner -
Ravi Viswanathan,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Forest Baskett,
10% owner -
Michael Powell,
Director -
Peter W. Sonsini,
10% owner -
Patrick J Kerins,
10% owner -
M James Barrett,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 14, L...,
-
Advisors Llc Orbi Med Capit...,
-
Jose Carlos Gutierrez Ramos,
See Remarks -
Paul Francis Miller,
Chief Scientific Officer -
Scott Eric Plevy,
Chief Scientific Officer -
Michael Vangsted Jensen,
Chief Financial Officer -
Antoine Awad,
Chief Operating Officer -
Michael Thomas Heffernan,
-
Lisa Kelly Croswell,
-
James P Flynn,
-
Mary Beth Dooley,
Head of Finance